11 April 2021 : Clinical Research
Analysis of Risk Factors for Thromboembolic Events in 88 Patients with COVID-19 Pneumonia in Wuhan, China: A Retrospective Descriptive Report
Wenyu Wang1CDE, Qingfeng Sun2CDF, Yongxia Bao1BC, Ming Liang3BC, Qingwei Meng4BC, Hong Chen1BC, Jianing Li1BC, Hongliang Wang5BC, Huiqing Li6BC, Ying Shi7BC, Zhaoguo Li1BF, Xinyan Wang1F, Shuai Zhao1F, Hongwei Wang1F, Jinling Xiao1F, Liyan Chen3F, Yan Zheng8F, Di Wang8F, Kaiyu Han1AEG*DOI: 10.12659/MSM.929708
Med Sci Monit 2021; 27:e929708
Table 1 Demographics and clinical characteristics of patients with COVID-19.
All patients (n=88) | Disease severity | |||||
---|---|---|---|---|---|---|
Critical patients (n=31) | Severe patients (n=33) | P value* | Common patients (n=24) | |||
Age -median (IQR) | 61.5 (55.0–68.8) | 66.5 (61.0–71.0) | 61.0 (53.0–66.0) | 0.11 | 56.0 (42.5–66.5) | |
Sex -n (%) | <0.05 | |||||
Female | 39 (44.3) | 10 (32.3) | 19 (57.6) | ** | 10 (41.7) | |
Male | 49 (55.7) | 21 (67.7) | 14 (42.4) | ** | 14 (58.3) | |
Padua score -n (%) | <0.001 | |||||
<4 | 50 (56.8) | 0 (0.0) | 26 (78.8) | ** | 24 (100.0) | |
≥4 | 38 (43.2) | 31 (100.0) | 7 (21.2) | ** | 0 (0.0) | |
D-dimer top-value – n (%) (normal range 0–0.5) | <0.001 | |||||
<5 ug/mL | 54 (61.4) | 4 (12.9) | 26 (78.8) | ** | 24 (100.0) | |
≥5 ug/mL | 34 (38.6) | 27 (87.1) | 7 (21.2) | ** | 0 (0.0) | |
DVT -n(%) | 19 (21.6) | 12 (38.7) | 7 (21.2) | 0.169 | 0 | |
Female | 10 (52.6) | 4 (33.3) | 6 (85.7) | ** | 0 | |
Male | 9 (47.4) | 8 (66.7) | 1 (14.3) | ** | 0 | |
Death – n (%) | 18 (20.5) | 18 (58.1) | 0 | <0.001 | 0 | |
DVT | 5 (27.8) | 5 (27.8) | 0 | ** | 0 | |
Padua score ≥4 | 18 (100.0) | 18 (100.0) | 0 | ** | 0 | |
D-dimer value ≥ 5ug/mL | 17 (94.4) | 17 (94.4) | 0 | ** | 0 | |
Lymphocyte count -median (IQR) (normal range 1.1–3.2×10/L) | 1.01 (0.60–1.35) | 0.55 (0.41–0.83) | 1.08 (0.74–1.46) | <0.001 | 1.29 (1.05–1.76) | |
LDH – median (IQR) (normal range 109–245 U/L) | 250.0 (178.5–485.8) | 543.0 (392.5–608.0) | 236.0 (179.0–324.5) | <0.001 | 174.0 (139.5–229.5) | |
CRP – median (IQR) (normal range 0–8 mg/L) | 32.33 (3.61–77.64) | 85.48 (53.14–114.31) | 19.62 (4.34–63.06) | <0.001 | 3.09 (0.10–18.00) | |
Age – median (IQR) | 67 (60–70) | 66 (61–74) | 0.553 | 62 (55.3–67.8) | 64 (56–71) | 0.36 |
Sex – n (%) | 0.704 | 0.421 | ||||
Female | 6 (33.3) | 4 (30.8) | ** | 19 (42.2) | 10 (52.6) | ** |
Male | 12 (66.7) | 9 (69.2) | ** | 26 (57.8) | 9 (47.4) | ** |
Padua score – n (%) | ** | <0.05 | ||||
<4 | 0 (0.0) | 0 (0.0) | ** | 24 (53.3) | 2 (10.5) | ** |
≥4 | 18 (100.0) | 13 (100.0) | ** | 21 (46.7) | 17 (89.5) | ** |
D-dimer top-value – n (%) (normal range 0–0.5) | 0.548 | <0.05 | ||||
<5 ug/mL | 1 (5.6) | 3 (23.1) | ** | 26 (57.8) | 4 (21.1) | ** |
≥5 ug/mL | 17 (94.4) | 10 (76.9) | ** | 19 (42.2) | 15 (78.9) | ** |
DVT -n(%) | 5 (27.8) | 7 (53.8) | 0 (0.0) | 19 (100.0) | ** | |
Female | ** | ** | ** | ** | ** | ** |
Male | ** | ** | ** | ** | ** | ** |
Death – n (%) | 18 (100.0) | 0 (0.0) | ** | ** | ||
DVT | ** | ** | ** | ** | ** | ** |
Padua score ≥4 | ** | ** | ** | ** | ** | ** |
D-dimer value ≥5 ug/mL | ** | ** | ** | ** | ** | ** |
Lymphocyte count – median (IQR) (normal range 1.1–3.2×10/L) | 0.47 (0.27–0.62) | 0.76 (0.57–0.89) | <0.05 | 0.89 (0.49–1.30) | 0.75 (0.52–0.98) | 0.142 |
LDH – median (IQR) (normal range 109–245 U/L) | 564.5 (465.3–677.5) | 451.5 (289.5–550.5) | 0.078 | 294.0 (184.3–556.8) | 461.0 (348.0–564.0) | 0.123 |
CRP – median (IQR) (normal range 0–8 mg/L) | 89.4 (56.7–120.3) | 65.2 (35.7–108.8) | 0.203 | 47.6 (7.4–84.5) | 72.4 (52.3–120.8) | 0.29 |
IQR – interquartile range; CRP – C-reactive protein; LDH – lactate dehydrogenase. * P values were calculated between critical and severe groups by Mann-Whitney U test, χ test, or Fisher’s exact test, as appropriate. |